- Home
- LRE vs LGVN Comparison
LRE vs LGVN Comparison
Compare LRE & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRE
- LGVN
- Stock Information
- Founded
- LRE 2001
- LGVN 2014
- Country
- LRE Japan
- LGVN United States
- Employees
- LRE N/A
- LGVN N/A
- Industry
- LRE
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- LRE
- LGVN Health Care
- Exchange
- LRE Nasdaq
- LGVN Nasdaq
- Market Cap
- LRE 22.5M
- LGVN 25.2M
- IPO Year
- LRE 2023
- LGVN 2021
- Fundamental
- Price
- LRE $1.35
- LGVN $1.56
- Analyst Decision
- LRE
- LGVN Strong Buy
- Analyst Count
- LRE 0
- LGVN 3
- Target Price
- LRE N/A
- LGVN $8.67
- AVG Volume (30 Days)
- LRE 5.3K
- LGVN 164.5K
- Earning Date
- LRE 01-01-0001
- LGVN 02-28-2025
- Dividend Yield
- LRE N/A
- LGVN N/A
- EPS Growth
- LRE N/A
- LGVN N/A
- EPS
- LRE 0.29
- LGVN N/A
- Revenue
- LRE $117,804,154.00
- LGVN $1,852,000.00
- Revenue This Year
- LRE N/A
- LGVN $208.32
- Revenue Next Year
- LRE N/A
- LGVN $43.96
- P/E Ratio
- LRE $4.61
- LGVN N/A
- Revenue Growth
- LRE 8.82
- LGVN 141.46
- 52 Week Low
- LRE $1.19
- LGVN $0.77
- 52 Week High
- LRE $13.76
- LGVN $6.40
- Technical
- Relative Strength Index (RSI)
- LRE 30.61
- LGVN 45.58
- Support Level
- LRE $1.20
- LGVN $1.53
- Resistance Level
- LRE $1.70
- LGVN $1.71
- Average True Range (ATR)
- LRE 0.10
- LGVN 0.13
- MACD
- LRE -0.02
- LGVN 0.02
- Stochastic Oscillator
- LRE 25.89
- LGVN 38.30
About LRE Lead Real Estate Co. Ltd
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. Predominantly, its revenue is generated from developing and selling single-family homes and condominiums. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.